Praxis Precision Medicine... (PRAX)
Company Description
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance.
Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor.
The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy.
It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Country | United States |
IPO Date | Oct 16, 2020 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 116 |
CEO | Marcio Silva De'Souza M.B.A. |
Contact Details
Address: 99 High Street Boston, Massachusetts United States | |
Website | https://www.praxismedicines.com |
Stock Details
Ticker Symbol | PRAX |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001689548 |
CUSIP Number | 74006W108 |
ISIN Number | US74006W2070 |
Employer ID | 00-0000000 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Marcio Silva De'Souza M.B.A. | President, Chief Executive Officer & Director |
Kelly McCue | Chief People Officer |
Timothy Edwin Kelly | Chief Financial Officer & Treasurer |
Alex Kane | Vice President of Investor Relations & Corporate Communications |
Alex Nemiroff J.D. | General Counsel & Secretary |
Alyssa J. S. Wyant | Chief Regulatory & Quality Officer |
Dr. Karl Hansen Ph.D. | Chief Technical Operations Officer |
Dr. Steven Petrou B.Sc. (Hons.), Ph.D. | Co-Founder & Chief Scientific Officer |
Lauren Mastrocola | Vice President of Finance & Principal Accounting Officer |
Megan T. Sniecinski | Chief Business Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 19, 2025 | SCHEDULE 13G | Filing |
Feb 28, 2025 | S-8 | Filing |
Feb 28, 2025 | S-8 | Filing |
Feb 28, 2025 | 10-K | Annual Report |
Feb 28, 2025 | 8-K | Current Report |
Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
Feb 14, 2025 | 4 | Filing |
Feb 14, 2025 | 4 | Filing |
Feb 14, 2025 | 4 | Filing |
Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |